Related Experiment Video
Updated: May 26, 2026

Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation
Published on: June 20, 2018
[Macrolide therapy on nasal mucosal persistent refractory inflammation after endoscopic sinus surgery]
1Othrhinolaryngology Hospital, First Affiliated Hospital, SUN Yat-san University, Otorhinolaryngology Institute of SUN Yat-san University, Guangzhou 510080, China.
Low-dose, long-term use of Klacid (clarithromycin) effectively treats persistent inflammation after endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS). This treatment is safe and well-tolerated, improving both symptoms and endoscopic outcomes.
Area of Science:
- Otolaryngology
- Pharmacology
- Inflammation Research
Background:
- Chronic rhinosinusitis (CRS) often involves persistent, refractory inflammation of the paranasal sinus mucosa.
- Endoscopic sinus surgery (ESS) is a common treatment for CRS, but some patients experience persistent inflammation postoperatively.
- Macrolide antibiotics, such as Klacid (clarithromycin), have demonstrated anti-inflammatory properties.
Purpose of the Study:
- To evaluate the clinical efficacy of low-dose, long-term Klacid in managing persistent refractory inflammation following ESS.
- To assess the safety and tolerability of this treatment regimen in CRS patients.
Main Methods:
- A study involving 13 patients with persistent refractory inflammation post-ESS for CRS.
- Patients received low-dose Klacid (250 mg/d) for 12-28 weeks, alongside standard treatments.
- Outcomes were assessed using visual analogue scale for symptoms and Lund-Kennedy scoring for nasal endoscopy.
Main Results:
- Twelve of 13 patients completed the treatment, showing remarkable improvement in both subjective symptoms and objective endoscopic findings.
- Overall outcomes were rated as very good in 6 patients and good in 6 patients.
- No recurrent sinusitis or adverse side effects were reported during the 6-month follow-up period.
Conclusions:
- Low-dose, long-term Klacid is an effective treatment for persistent refractory inflammation of the nasal mucosa after ESS in CRS patients.
- Klacid demonstrates a favorable safety profile and good tolerability for this patient group.
- This therapeutic approach offers significant clinical benefits for managing challenging post-ESS inflammation.
Related Concept Videos
Epistaxis
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
Mitral Stenosis III: Medical Management
Suctioning the Nasopharyngeal Airway
Equipment Required
Tonsillitis II: Management
Endocarditis III: Medical Management
